Loading…
Nath Bio-Genes (India) (NATHBIOGEN)₹139.65+1.01%Other Agricultural Products
In the Jun 2026 quarter (consolidated), Nath Bio-Genes (India) reported sales of ₹328 Cr, up 15.5% from Jun 2025, and net profit of ₹31.92 Cr, up 14.3% year on year. For the year to Mar 2026, sales were ₹446 Cr and net profit ₹41.89 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 23.03 | 32.03 | 43.01 | 244 | 32.03 | 37.06 | 52.01 | 284 | 44.06 | 65.99 | 52.07 | 328 |
| Expenses | 18.06 | 26.12 | 39.13 | 208 | 27.12 | 29.11 | 52.21 | 255 | 38.13 | 62.24 | 47.15 | 294 |
| Operating Profit | 5.02 | 6.03 | 4.02 | 37.16 | 5.02 | 8.03 | 0.00 | 29.12 | 6.03 | 4.01 | 4.02 | 35.12 |
| OPM % | 22.0% | 18.0% | 9.0% | 15.1% | 15.0% | 22.1% | 0.8% | 10.0% | 14.1% | 5.0% | 9.0% | 11.0% |
| Other Income | 0.00 | 3.01 | 1.01 | 0.00 | 0.00 | 0.00 | 4.01 | 4.02 | 4.01 | 4.01 | 4.01 | 3.01 |
| Interest | 2.01 | 3.01 | 1.01 | 2.01 | 3.01 | 4.01 | 1.01 | 3.01 | 4.01 | 5.01 | 5.01 | 4.01 |
| Depreciation | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
| Profit before tax | 1.99 | 4.99 | 2.99 | 33.95 | 0.99 | 3.99 | 1.99 | 28.98 | 4.99 | 1.99 | 1.99 | 32.95 |
| Tax % | 19.1% | 17.0% | 19.1% | 1.0% | −3.0% | 30.0% | 30.0% | 2.0% | 12.0% | 35.0% | 100.1% | 2.0% |
| Exceptional items | 0.00 | 2.49 | 0.94 | 0.00 | 0.00 | 0.00 | 0.53 | 2.01 | 1.81 | 1.80 | 0.00 | 1.16 |
| Net Profit | 1.99 | 3.99 | 2.99 | 32.90 | 0.99 | 2.99 | 0.99 | 27.93 | 4.99 | 1.99 | 0.00 | 31.92 |
| EPS (Rs) | 0.78 | 2.01 | 1.37 | 17.54 | 0.57 | 1.38 | 0.77 | 14.87 | 2.53 | 0.83 | 0.00 | 16.97 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 230 | 234 | 248 | 268 | 446 | 490 |
| Expenses | 194 | 186 | 199 | 218 | 394 | 441 |
| Operating Profit | 37.15 | 49.22 | 50.21 | 51.21 | 52.20 | 49.18 |
| OPM % | 16.0% | 21.0% | 20.0% | 19.0% | 12.0% | 10.0% |
| Other Income | −87.33 | 1.01 | 4.01 | 4.01 | 14.05 | 15.04 |
| Interest | 11.01 | 10.01 | 9.01 | 11.02 | 16.02 | 18.04 |
| Depreciation | 3.01 | 3.01 | 3.01 | 4.01 | 4.01 | 4.04 |
| Profit before tax | −62.97 | 35.97 | 41.99 | 40.94 | 45.99 | 41.92 |
| Tax % | 6.0% | 3.0% | 5.0% | 5.0% | 10.0% | — |
| Exceptional items | −90.94 | 0.00 | 3.28 | −0.46 | 5.39 | 4.77 |
| Net Profit | −66.85 | 34.92 | 39.89 | 38.89 | 41.89 | 38.90 |
| EPS (Rs) | −35.45 | 18.41 | 20.82 | 20.29 | 21.90 | 20.33 |
| Dividend payout % | −6.0% | 11.0% | 10.0% | 10.1% | 9.0% | — |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 18.91 | 18.91 | 18.91 | 18.92 | 18.92 |
| Reserves | 521 | 552 | 589 | 624 | 659 |
| Borrowings | 92.57 | 105 | 109 | 122 | 137 |
| Other Liabilities | 105 | 113 | 159 | 258 | 277 |
| Total Liabilities | 736 | 790 | 876 | 1,023 | 1,093 |
| Fixed Assets | 244 | 243 | 248 | 249 | 248 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 4.99 | 4.99 | 5.99 | 5.99 | 6.01 |
| Other Assets | 488 | 541 | 622 | 768 | 839 |
| Inventories | 219 | 208 | 230 | 337 | 450 |
| Trade receivables | 86.33 | 97.43 | 94.41 | 89.30 | 85.27 |
| Cash & equivalents | 4.01 | 38.01 | 76.92 | 88.91 | 75.97 |
| Total Assets | 736 | 790 | 876 | 1,023 | 1,093 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 17.04 | 38.09 | 75.16 | 18.04 | −13.04 |
| Cash from investing activity | −19.97 | −2.99 | −26.94 | −3.99 | 2.99 |
| Cash from financing activity | −22.04 | −2.01 | −8.01 | −2.01 | −4.01 |
| Net cash flow | −24.99 | 34.02 | 38.99 | 11.01 | −13.01 |
| Capex | 1.13 | 2.54 | 26.81 | 7.93 | 3.02 |
| Free cash flow | 15.99 | 35.96 | 47.97 | 9.99 | −15.98 |
| CFO / OP % | 54.0% | 80.0% | 150.0% | 37.0% | −22.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 136 | 152 | 139 | 121 | 70 |
| Inventory days | — | 4,389 | — | — | — |
| Days payable | — | 586 | — | — | — |
| Cash conversion cycle | 137 | 3,955 | 140 | 122 | 71 |
| Working capital days | 426 | 414 | 341 | 320 | 252 |
| ROCE % | — | 7.0% | 7.0% | 7.0% | 7.0% |
For the Jun 2026 quarter, Nath Bio-Genes (India) reported sales of ₹328 Cr, up 15.5% year on year and net profit of ₹31.92 Cr, up 14.3% year on year. The operating margin was 11.0%.
Nath Bio-Genes (India)'s sales for the year to Mar 2026 were ₹446 Cr; over the last twelve months they were ₹490 Cr.
Net profit for the year to Mar 2026 was ₹41.89 Cr, and ₹38.90 Cr over the last twelve months. Earnings per share over the same trailing period were ₹20.33.
Nath Bio-Genes (India) reported borrowings of ₹137 Cr at Mar 2026, against cash and equivalents of ₹75.97 Cr.
Cash from operations was −₹13.04 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹15.98 Cr.